US FDA’s Non-Guidance On Osteoarthritis Drugs: Starting Over On Structural Claims

Agency essentially ruling out use of structural endpoints to support disease progression claims for osteoarthritis drugs in new draft guidance.

The US FDA’s new draft guidance on structural endpoints for osteoarthritis drug development is an unusual example of the agency’s “just-say-it” approach to guidance writing.

The text of the guidance is just over two pages – and shorter than the three pages of cover material...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approval Standards

More from Pathways & Standards